...
首页> 外文期刊>Clinical & translational oncology : >Intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma: Topography of locoregional recurrences and long-term outcomes
【24h】

Intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma: Topography of locoregional recurrences and long-term outcomes

机译:术中放疗治疗可切除的局部晚期胃腺癌:局部复发和长期预后的地形图

获取原文
获取原文并翻译 | 示例

摘要

Introduction: To report feasibility, tolerance, anatomical sites of upper abdominal locoregional recurrence and long-term outcome of gastric cancer patients treated with surgery and a component of intraoperative electron beam radiotherapy (IORT). Materials and methods: From January 1995 to December 2010, 32 patients with primary gastric adenocarcinoma treated with curative resection (R0) [total gastrectomy (n = 9; 28 %), subtotal (n = 23; 72 %) and D2 lymphadenectomy in all patients] and apparent disease confined to locoregional area [Stage: II (n = 15; 47 %), III (n = 17; 53 %)] were treated with a component of IORT (IORT applicator size 5-9 cm in diameter, dose 10-15 Gy, beam energy 6-5 MeV) over the celiac axis and peripancreatic nodal areas. Sixteen (50 %) patients also received adjuvant treatment (external beam radiotherapy n = 6, chemoradiation n = 9, chemotherapy alone n = 1). Results: With a median follow-up time of 40 months (range, 2-60), locoregional recurrence was observed in five (16 %) patients (4 nodal in hepatic hilum and 1 anastomotic). Only pN1 patients developed locoregional relapse. No recurrence was observed in the IORT-treated target volume (celiac trunk and peripancreatic nodes). Overall survival at 5 years was 54.6 % (95 % CI: 48.57-60.58). Postoperative mortality was 6 % (n = 2) and postoperative complications 19 % (n = 6). Conclusions: It is feasible to integrate IORT as a component of radiotherapy in combined modality therapy of gastric cancer. Local control is high in the radiation boosted area, but marginal regional extension (in particular, involving the hepatic hilum) might be considered as part of the anatomic IORT target volume at risk in pN+ patients.
机译:简介:报告手术治疗和术中电子束放射治疗(IORT)组成部分治疗的胃癌患者的可行性,耐受性,上腹部局部复发的解剖部位和远期结局。资料和方法:自1995年1月至2010年12月,对32例原发性胃腺癌患者行根治性切除术(R0)[全部胃切除术(n = 9; 28%),小计(n = 23; 72%)和D2淋巴结清扫术患者]和局限在局部区域的明显疾病[阶段:II(n = 15; 47%),III(n = 17; 53%)]用IORT组件(直径为5-9 cm的IORT涂抹器,剂量为10-15 Gy,束能量6-5 MeV)在腹腔轴和胰周结区。十六名(50%)患者也接受了辅助治疗(外部束放射疗法n = 6,化学放射疗法n = 9,仅化学疗法n = 1)。结果:中位随访时间为40个月(范围2-60),在5例(16%)患者中观察到局部复发(肝门4例,吻合1例)。仅pN1患者发展局部复发。在IORT治疗的目标体积(cel干和胰周结节)中未观察到复发。 5年总生存率为54.6%(95%CI:48.57-60.58)。术后死亡率为6%(n = 2),术后并发症为19%(n = 6)。结论:将IORT作为放疗的组成部分整合到胃癌的联合治疗中是可行的。辐射增强区域的局部控制很高,但边缘区域扩展(特别是涉及肝门)可能被视为pN +患者有风险的IORT解剖目标体积的一部分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号